← SynDRA
HMN-214
SynDRA canonical compound SYN0039225 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PLK1 |
|---|
| Mechanism of action | PLK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PLK1 INHIBITOR
- Serine/threonine-protein kinase PLK1 inhibitor
- PLK inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PAK6
- PHKG2
- PFKP
- PDXK
- PDGFRB
- PCYT1A
- PASK
- PAK4
- PIM2
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- PIM1
- PIP4K2A
- NLK
- PRKACB
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACA
- PIP4K2C
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- NQO2
- NEK9
- PRKCI
- MAPK14
- MAPKAPK2
- MAPK9
Cross-references
Synonyms
- IVX-214
- N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide
- (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
- HMN 214
- RefChem:926547
- MFCD12756255
- UNII-94E9UR0RFR
- OCKHRKSTDPOHEN-BQYQJAHWSA-N
- MLS006011062
- SCHEMBL5173713
- CHEBI:91440
- GLXC-03301
- HMS5079E10
- EX-A1158
- HMN-214?
- NSC800767
- s1485
- AKOS027270086
- CCG-268936
- CS-0202
- NSC-800767
- SDCCGSBI-0654370.P001
- NCGC00386148-04
- NCGC00386148-08
- AC-32847
- AS-74407
- HY-12045
- SMR004702854
- SY122299
- SW219842-1
- SR-03000003276
- SR-03000003276-1
- BRD-K70511574-001-01-0
- BRD-K70511574-001-06-9
Look up HMN-214 in the interactive SynDRA portal →